Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

D J Diekema; S A Messer; R J Hollis; R N Jones; M A Pfaller

doi:10.1128/JCM.41.8.3623-3626.2003

Back

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

Journal article

Open access

Peer reviewed

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

D J Diekema, S A Messer, R J Hollis, R N Jones and M A Pfaller

Journal of clinical microbiology, Vol.41(8), pp.3623-3626

08/2003

DOI: 10.1128/JCM.41.8.3623-3626.2003

PMCID: PMC179829

PMID: 12904365

Files and links (1)

url

https://doi.org/10.1128/JCM.41.8.3623-3626.2003View

Published (Version of record) Open Access

Abstract

We examined the in vitro activity of caspofungin, posaconazole, voriconazole, ravuconazole, itraconazole, and amphotericin B against 448 recent clinical mold isolates. The endpoint for reading caspofungin was the minimum effective concentration (MEC). Among the triazoles, posaconazole was most active, inhibiting 95% of isolates at <or=1 microg/ml, followed by ravuconazole (91%), voriconazole (90%), and itraconazole (79%). Caspofungin and amphotericin B inhibited 93% and 89% of isolates at <or=1 microg/ml, respectively, with caspofungin demonstrating an MEC 90 of 0.12 microg/ml. All three new triazoles and caspofungin inhibited >95% of Aspergillus spp. at <or=1 microg/ml compared to 83% for itraconazole and 91% for amphotericin B. Amphotericin B inhibited only 38% of Aspergillus terreus isolates at <or=1 microg/ml, whereas the three new triazoles and caspofungin inhibited all A. terreus at <or=0.5 microg/ml. The new triazoles and caspofungin have excellent in vitro activity against a very large collection of recent clinical isolates of Aspergillus spp., and some in vitro activity against selected other filamentous fungi.

Fungi - drug effects

Peptides

Humans

Amphotericin B - pharmacology

Fungi - isolation & purification

Mycoses

Penicillium - drug effects

Pyrimidines - pharmacology

Itraconazole - pharmacology

Aspergillus - drug effects

Peptides, Cyclic

Triazoles - pharmacology

Caspofungin

Voriconazole

Echinocandins

Anti-Bacterial Agents - pharmacology

Thiazoles - pharmacology

Lipopeptides

Microbial Sensitivity Tests - methods

Details

Title: Subtitle: Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi
Creators: D J Diekema - Department of Internal Medicine,University of Iowa College of Medicine, Iowa City, IA 52242, USA. daniel-diekema@uiowa.edu
S A Messer
R J Hollis
R N Jones
M A Pfaller
Resource Type: Journal article
Publication Details: Journal of clinical microbiology, Vol.41(8), pp.3623-3626
DOI: 10.1128/JCM.41.8.3623-3626.2003
PMID: 12904365
PMCID: PMC179829
NLM abbreviation: J Clin Microbiol
ISSN: 0095-1137
eISSN: 1098-660X
Publisher: United States
Language: English
Date published: 08/2003
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986258402771

Metrics

27 Record Views

300 Times Cited - Web of Science